Biotech Values

[investorgold2002]

agreed

two reasons

1. Niaspan(ER niacin) sells for $1 billion. its usage would be curtailed by doctor considering adverse event risk of stroke

2. AMR101 is ONLY drug to have proven benefits over CV outcomes in a combotheraypy with statin. Niaspan had hopes via AINM-HIGH..but that is gone now. We know fibrates have fared poorly on this regard

Market value of AMR101 would further increase with this news